Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Operating Margin (2023 - 2025)

Entrada Therapeutics has reported Operating Margin over the past 3 years, most recently at 3249.27% for Q4 2025.

  • Quarterly results put Operating Margin at 3249.27% for Q4 2025, down 323358.0% from a year ago — trailing twelve months through Dec 2025 was 621.13% (down 64344.0% YoY), and the annual figure for FY2025 was 621.13%, down 64344.0%.
  • Operating Margin for Q4 2025 was 3249.27% at Entrada Therapeutics, down from 2915.18% in the prior quarter.
  • Over the last five years, Operating Margin for TRDA hit a ceiling of 56.42% in Q2 2024 and a floor of 3249.27% in Q4 2025.
  • Median Operating Margin over the past 3 years was 56.29% (2023), compared with a mean of 731.33%.
  • Biggest five-year swings in Operating Margin: soared 14612bps in 2024 and later tumbled -323358bps in 2025.
  • Entrada Therapeutics' Operating Margin stood at 11.72% in 2023, then plummeted by -234bps to 15.69% in 2024, then crashed by -20612bps to 3249.27% in 2025.
  • The last three reported values for Operating Margin were 3249.27% (Q4 2025), 2915.18% (Q3 2025), and 2402.51% (Q2 2025) per Business Quant data.